| pubmed-article:20820776 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C2697913 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C0019721 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1704241 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1708715 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C2346689 | lld:lifeskim |
| pubmed-article:20820776 | lifeskim:mentions | umls-concept:C1523987 | lld:lifeskim |
| pubmed-article:20820776 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:20820776 | pubmed:dateCreated | 2010-9-27 | lld:pubmed |
| pubmed-article:20820776 | pubmed:abstractText | During HLA class II synthesis in antigen-presenting cells, the invariant chain (Ii) not only stabilizes HLA class II complexes in the endoplasmic reticulum, but also mediates their transport to specialized lysosomal antigen-loading compartments termed MIICs. This study explores an alternative HLA class II presentation pathway in leukemic blasts that involves proteasome and transporter associated with antigen processing (TAP)-dependent peptide loading. Although HLA-DR did associate with Ii, Ii silencing in the human class II-associated invariant chain peptide (CLIP)-negative KG-1 myeloid leukemic cell line did not affect total and plasma membrane expression levels of HLA-DR, as determined by western blotting and flow cytometry. Since HLA-DR expression does require peptide binding, we examined the role of endogenous antigen-processing machinery in HLA-DR presentation by CLIP(-) leukemic blasts. The suppression of proteasome and TAP function using various inhibitors resulted in decreased HLA-DR levels in both CLIP(-) KG-1 and ME-1 blasts. Simultaneous inhibition of TAP and Ii completely down-modulated the expression of HLA-DR, demonstrating that together these molecules form the key mediators of HLA class II antigen presentation in leukemic blasts. By the use of a proteasome- and TAP-dependent pathway for HLA class II antigen presentation, CLIP(-) leukemic blasts might be able to present a broad range of endogenous leukemia-associated peptides via HLA class II to activate leukemia-specific CD4(+) T cells. | lld:pubmed |
| pubmed-article:20820776 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20820776 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20820776 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20820776 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:20820776 | pubmed:issn | 1432-0851 | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:OssenkoppeleG... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:ZevenbergenAd... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:Ostrand-Rosen... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:van de... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:RessingMaaike... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:ChamuleauMart... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:SouwerYuriY | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:WiertzEmmanue... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:van HamS... | lld:pubmed |
| pubmed-article:20820776 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:20820776 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20820776 | pubmed:volume | 59 | lld:pubmed |
| pubmed-article:20820776 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20820776 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20820776 | pubmed:pagination | 1825-38 | lld:pubmed |
| pubmed-article:20820776 | pubmed:dateRevised | 2010-12-3 | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:meshHeading | pubmed-meshheading:20820776... | lld:pubmed |
| pubmed-article:20820776 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20820776 | pubmed:articleTitle | Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. | lld:pubmed |
| pubmed-article:20820776 | pubmed:affiliation | Department of Hematology, Cancer Center Amsterdam, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. m.luijn@vumc.nl | lld:pubmed |
| pubmed-article:20820776 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20820776 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:972 | entrezgene:pubmed | pubmed-article:20820776 | lld:entrezgene |
| entrez-gene:6890 | entrezgene:pubmed | pubmed-article:20820776 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20820776 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20820776 | lld:entrezgene |
